Keita Mori, MBA,
SanBio Co., Ltd. President
SanBio, Inc. Co-CEO, Chairman
Mr. Mori has been Co-Chief Executive Officer and has served as a member of the Board since SanBio's inception in 2001. Prior to founding SanBio, Mr. Mori was Head of New Product Development from 2000 to 2001 at Xuma, an informatics startup in San Francisco. From 1993 to 1999, Mr. Mori held positions of increasing responsibility in R&D and Manufacturing at Kirin Holdings, Ltd. in Japan. Mr. Mori holds an MBA degree from the University of California, Berkeley and a master's degree in Biochemistry from the University of Tokyo.
SanBio Co., Ltd. Exective Chairman
SanBio, Inc. Co-CEO
Mr. Kawanishi served as SanBio's Chairman of the Board from 2001 to 2005 and has been Co-Chief Executive Officer and a member of the Board since 2005. Prior to founding SanBio, Mr. Kawanishi co-founded CareNet, Inc. (TSE: 2150) and was Executive Vice President from 1996 to 1999. At CareNet, Mr. Kawanishi established eHealthcare in Japan. From 1993 to 1996, Mr. Kawanishi was a management consultant at the Boston Consulting Group. Mr. Kawanishi has a master's degree in Biochemistry from the University of Tokyo.
Damien Bates, MD, PhD, FRACS, MBA,
Chief Medical Officer and Head of Research
Dr. Bates is a board certified reconstructive surgeon who has held senior positions in clinical development and medical affairs at Baxter, Organogenesis, and Allergan. In these roles, Dr. Bates specialized in the surgical applications of regenerative medicine and has the distinction of leading the first and only successful regulatory approval of an allogeneic cell therapy product in the US. Dr. Bates received his medical degree from the University of Sydney, his PhD in Developmental Biology from the University of Melbourne, and his MBA from the Wharton Business School.
Mohammad El-Kalay, Ph.D.,
Senior Vice President, Technical Operations
Dr. El-Kalay has one of the industry’s most extensive backgrounds in the development and manufacturing of cell therapies. He served as a key team member in pioneering companies such as Applied Immune Sciences, Systemix, and Osiris Therapeutics, then led technical operations teams in Vice President roles at Morphogen Pharmaceuticals, Telos Pharmaceuticals, and MicroIslet. Dr. El-Kalay founded a cellular therapy company EyeCyte, focusing on retinal diseases, and served as its Chief Executive Officer until 2013. Recently he served as Vice President of Process Development and Manufacturing at StemCells, Inc. and as Vice President of Technical Operations at Sangamo Therapeutics.
Dr. El-Kalay holds a Ph.D. in Chemical/Biomedical from Strathclyde University, Glasgow.
Michael P. McGrogan, Ph.D.,
Senior Production Development Fellow
Dr. McGrogan joined SanBio in 2003. Dr. McGrogan has over 25 years of biopharmaceutical R&D and production development experience. Prior to joining SanBio, Dr. McGrogan was Vice President of Research and Development at Layton BioScience (1996 to 2003). At Layton, Dr. McGrogan successfully managed the first cell therapy product to enter clinical trials for a CNS application, LBS-Neuron, from inception through a Phase II clinical trial. Prior to Layton, Dr. McGrogan held positions of increasing responsibility at several biotech companies including Berlex Biosciences, Invitron, and Cetus. Dr. McGrogan holds a Ph.D. in Molecular and Cellular Biology from Washington University School of Medicine, St. Louis, Missouri.
Corporate Officer, Management Administration
Previously, Mr. Kakutani was Executive Officer and General Manager of Finance Department of CareNet, Inc. (TSE, Mothers: 2150). Mr. Kakutani is a US Certified Public Accountant.